U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H21N3O
Molecular Weight 199.2936
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIETHYLCARBAMAZINE

SMILES

CCN(CC)C(=O)N1CCN(C)CC1

InChI

InChIKey=RCKMWOKWVGPNJF-UHFFFAOYSA-N
InChI=1S/C10H21N3O/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13/h4-9H2,1-3H3

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including http://filobase.bicpu.edu.in/banocide.pdf

Diethylcarbamazine is used in humans, dogs and cats for the treatment of parasitic infections, including pulmonary eosinophilia, loiasis, and lymphatic filariasis. The exact mechanism of its action is unknown, however some studies showed the involvment of inducible nitric-oxide synthase and the cyclooxygenase pathway. Although there is no information on whether the drug is marketed in the USA and Europe, it is currently used in India.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
BANOCIDE

Approved Use

Used for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori.
Curative
BANOCIDE

Approved Use

Used for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori.
Curative
BANOCIDE

Approved Use

Used for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
500 ng/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIETHYLCARBAMAZINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
637 ng/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIETHYLCARBAMAZINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5840 ng × h/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIETHYLCARBAMAZINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
7220 ng × h/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIETHYLCARBAMAZINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
14.6 h
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIETHYLCARBAMAZINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
11.4 h
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIETHYLCARBAMAZINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
6 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg/kg, 1 times / day
Sources:
unhealthy, 12 to 69 years
n = 11
Health Status: unhealthy
Condition: filariasis
Age Group: 12 to 69 years
Sex: M+F
Population Size: 11
Sources:
Other AEs: Fever, Pruritus...
Other AEs:
Fever (63.6%)
Pruritus (9.1%)
Giddiness (9.1%)
Joint ache (9.1%)
Sources:
2 mg/kg 3 times / day multiple, oral
Studied dose
Dose: 2 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg/kg, 3 times / day
Sources:
unhealthy, 13 to 46 years
n = 11
Health Status: unhealthy
Condition: filariasis
Age Group: 13 to 46 years
Sex: M+F
Population Size: 11
Sources:
Other AEs: Fever, Nausea...
Other AEs:
Fever
Nausea (27.3%)
Vomiting (18.2%)
Abdominal discomfort (9.1%)
Sources:
50 mg multiple, oral
Studied dose
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 37 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 37 years
Sex: M
Population Size: 10
Sources:
Other AEs: Lymphadenopathy, Papular urticarial eruption...
Other AEs:
Lymphadenopathy (100%)
Papular urticarial eruption (30%)
Proteinuria (10%)
Visual field constriction (20%)
Optic nerve pallor (10%)
Corneal opacity (90%)
Anterior uveitis (10%)
Chorioretinitis (10%)
Sources:
300 mg multiple, topical
Studied dose
Dose: 300 mg
Route: topical
Route: multiple
Dose: 300 mg
Sources:
unhealthy, 40 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 40 years
Sex: M
Population Size: 10
Sources:
Other AEs: Lymphadenopathy, Papular urticarial eruption...
Other AEs:
Lymphadenopathy (100%)
Papular urticarial eruption (70%)
Proteinuria (30%)
Visual field constriction (10%)
Optic nerve pallor (20%)
Corneal opacity (80%)
Anterior uveitis (30%)
Chorioretinitis (30%)
Sources:
6 mg/kg 1 times / day single, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 6 mg/kg, 1 times / day
Co-administed with::
ivermectin(200 ug/kg; single)
albendazole(400 mg; single)
Sources:
unhealthy, median age 35 years
n = 43
Health Status: unhealthy
Condition: Filariasis
Age Group: median age 35 years
Sex: M+F
Population Size: 43
Sources:
Other AEs: Fatigue, Nausea...
Other AEs:
Fatigue (grade 2, 5%)
Nausea (grade 2, 2%)
Vomiting (grade 2, 2%)
Joint pain (grade 2, 2%)
Eye swelling (grade 2, 2%)
Rash (grade 2, 2%)
Dyspnea (grade 2, 2%)
Sources:
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Other AEs: Fever, Headache...
Other AEs:
Fever (69%)
Headache (65%)
Vertigo (57%)
Malaise (49%)
Chills (45%)
Joint pain (40%)
Abdominal pain (37%)
Chest pain (33%)
Nausea (28%)
Neck pain (24%)
Vomiting (16%)
Muscular pain (14%)
Lymph node tenderness (38%)
Epididymal tenderness (34%)
Nodule (15%)
Tinnitus (8%)
Convulsion (2%)
Eruption (<1%)
Shock (<1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Fever 63.6%
6 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg/kg, 1 times / day
Sources:
unhealthy, 12 to 69 years
n = 11
Health Status: unhealthy
Condition: filariasis
Age Group: 12 to 69 years
Sex: M+F
Population Size: 11
Sources:
Giddiness 9.1%
6 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg/kg, 1 times / day
Sources:
unhealthy, 12 to 69 years
n = 11
Health Status: unhealthy
Condition: filariasis
Age Group: 12 to 69 years
Sex: M+F
Population Size: 11
Sources:
Joint ache 9.1%
6 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg/kg, 1 times / day
Sources:
unhealthy, 12 to 69 years
n = 11
Health Status: unhealthy
Condition: filariasis
Age Group: 12 to 69 years
Sex: M+F
Population Size: 11
Sources:
Pruritus 9.1%
6 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg/kg, 1 times / day
Sources:
unhealthy, 12 to 69 years
n = 11
Health Status: unhealthy
Condition: filariasis
Age Group: 12 to 69 years
Sex: M+F
Population Size: 11
Sources:
Fever
2 mg/kg 3 times / day multiple, oral
Studied dose
Dose: 2 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg/kg, 3 times / day
Sources:
unhealthy, 13 to 46 years
n = 11
Health Status: unhealthy
Condition: filariasis
Age Group: 13 to 46 years
Sex: M+F
Population Size: 11
Sources:
Vomiting 18.2%
2 mg/kg 3 times / day multiple, oral
Studied dose
Dose: 2 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg/kg, 3 times / day
Sources:
unhealthy, 13 to 46 years
n = 11
Health Status: unhealthy
Condition: filariasis
Age Group: 13 to 46 years
Sex: M+F
Population Size: 11
Sources:
Nausea 27.3%
2 mg/kg 3 times / day multiple, oral
Studied dose
Dose: 2 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg/kg, 3 times / day
Sources:
unhealthy, 13 to 46 years
n = 11
Health Status: unhealthy
Condition: filariasis
Age Group: 13 to 46 years
Sex: M+F
Population Size: 11
Sources:
Abdominal discomfort 9.1%
2 mg/kg 3 times / day multiple, oral
Studied dose
Dose: 2 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg/kg, 3 times / day
Sources:
unhealthy, 13 to 46 years
n = 11
Health Status: unhealthy
Condition: filariasis
Age Group: 13 to 46 years
Sex: M+F
Population Size: 11
Sources:
Anterior uveitis 10%
50 mg multiple, oral
Studied dose
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 37 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 37 years
Sex: M
Population Size: 10
Sources:
Chorioretinitis 10%
50 mg multiple, oral
Studied dose
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 37 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 37 years
Sex: M
Population Size: 10
Sources:
Optic nerve pallor 10%
50 mg multiple, oral
Studied dose
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 37 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 37 years
Sex: M
Population Size: 10
Sources:
Proteinuria 10%
50 mg multiple, oral
Studied dose
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 37 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 37 years
Sex: M
Population Size: 10
Sources:
Lymphadenopathy 100%
50 mg multiple, oral
Studied dose
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 37 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 37 years
Sex: M
Population Size: 10
Sources:
Visual field constriction 20%
50 mg multiple, oral
Studied dose
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 37 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 37 years
Sex: M
Population Size: 10
Sources:
Papular urticarial eruption 30%
50 mg multiple, oral
Studied dose
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 37 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 37 years
Sex: M
Population Size: 10
Sources:
Corneal opacity 90%
50 mg multiple, oral
Studied dose
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 37 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 37 years
Sex: M
Population Size: 10
Sources:
Visual field constriction 10%
300 mg multiple, topical
Studied dose
Dose: 300 mg
Route: topical
Route: multiple
Dose: 300 mg
Sources:
unhealthy, 40 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 40 years
Sex: M
Population Size: 10
Sources:
Lymphadenopathy 100%
300 mg multiple, topical
Studied dose
Dose: 300 mg
Route: topical
Route: multiple
Dose: 300 mg
Sources:
unhealthy, 40 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 40 years
Sex: M
Population Size: 10
Sources:
Optic nerve pallor 20%
300 mg multiple, topical
Studied dose
Dose: 300 mg
Route: topical
Route: multiple
Dose: 300 mg
Sources:
unhealthy, 40 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 40 years
Sex: M
Population Size: 10
Sources:
Anterior uveitis 30%
300 mg multiple, topical
Studied dose
Dose: 300 mg
Route: topical
Route: multiple
Dose: 300 mg
Sources:
unhealthy, 40 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 40 years
Sex: M
Population Size: 10
Sources:
Chorioretinitis 30%
300 mg multiple, topical
Studied dose
Dose: 300 mg
Route: topical
Route: multiple
Dose: 300 mg
Sources:
unhealthy, 40 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 40 years
Sex: M
Population Size: 10
Sources:
Proteinuria 30%
300 mg multiple, topical
Studied dose
Dose: 300 mg
Route: topical
Route: multiple
Dose: 300 mg
Sources:
unhealthy, 40 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 40 years
Sex: M
Population Size: 10
Sources:
Papular urticarial eruption 70%
300 mg multiple, topical
Studied dose
Dose: 300 mg
Route: topical
Route: multiple
Dose: 300 mg
Sources:
unhealthy, 40 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 40 years
Sex: M
Population Size: 10
Sources:
Corneal opacity 80%
300 mg multiple, topical
Studied dose
Dose: 300 mg
Route: topical
Route: multiple
Dose: 300 mg
Sources:
unhealthy, 40 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 40 years
Sex: M
Population Size: 10
Sources:
Dyspnea grade 2, 2%
6 mg/kg 1 times / day single, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 6 mg/kg, 1 times / day
Co-administed with::
ivermectin(200 ug/kg; single)
albendazole(400 mg; single)
Sources:
unhealthy, median age 35 years
n = 43
Health Status: unhealthy
Condition: Filariasis
Age Group: median age 35 years
Sex: M+F
Population Size: 43
Sources:
Eye swelling grade 2, 2%
6 mg/kg 1 times / day single, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 6 mg/kg, 1 times / day
Co-administed with::
ivermectin(200 ug/kg; single)
albendazole(400 mg; single)
Sources:
unhealthy, median age 35 years
n = 43
Health Status: unhealthy
Condition: Filariasis
Age Group: median age 35 years
Sex: M+F
Population Size: 43
Sources:
Joint pain grade 2, 2%
6 mg/kg 1 times / day single, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 6 mg/kg, 1 times / day
Co-administed with::
ivermectin(200 ug/kg; single)
albendazole(400 mg; single)
Sources:
unhealthy, median age 35 years
n = 43
Health Status: unhealthy
Condition: Filariasis
Age Group: median age 35 years
Sex: M+F
Population Size: 43
Sources:
Nausea grade 2, 2%
6 mg/kg 1 times / day single, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 6 mg/kg, 1 times / day
Co-administed with::
ivermectin(200 ug/kg; single)
albendazole(400 mg; single)
Sources:
unhealthy, median age 35 years
n = 43
Health Status: unhealthy
Condition: Filariasis
Age Group: median age 35 years
Sex: M+F
Population Size: 43
Sources:
Rash grade 2, 2%
6 mg/kg 1 times / day single, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 6 mg/kg, 1 times / day
Co-administed with::
ivermectin(200 ug/kg; single)
albendazole(400 mg; single)
Sources:
unhealthy, median age 35 years
n = 43
Health Status: unhealthy
Condition: Filariasis
Age Group: median age 35 years
Sex: M+F
Population Size: 43
Sources:
Vomiting grade 2, 2%
6 mg/kg 1 times / day single, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 6 mg/kg, 1 times / day
Co-administed with::
ivermectin(200 ug/kg; single)
albendazole(400 mg; single)
Sources:
unhealthy, median age 35 years
n = 43
Health Status: unhealthy
Condition: Filariasis
Age Group: median age 35 years
Sex: M+F
Population Size: 43
Sources:
Fatigue grade 2, 5%
6 mg/kg 1 times / day single, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 6 mg/kg, 1 times / day
Co-administed with::
ivermectin(200 ug/kg; single)
albendazole(400 mg; single)
Sources:
unhealthy, median age 35 years
n = 43
Health Status: unhealthy
Condition: Filariasis
Age Group: median age 35 years
Sex: M+F
Population Size: 43
Sources:
Muscular pain 14%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Nodule 15%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Vomiting 16%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Convulsion 2%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Neck pain 24%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Nausea 28%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Chest pain 33%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Epididymal tenderness 34%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Abdominal pain 37%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Lymph node tenderness 38%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Joint pain 40%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Chills 45%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Malaise 49%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Vertigo 57%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Headache 65%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Fever 69%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Tinnitus 8%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Eruption <1%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Shock <1%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Overview

Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [Activation >10 uM]
no
no
no
no
no
yes [Inhibition 10 uM]
yes [Inhibition 10 uM]
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely
no
no (co-administration study)
Comment: Coadministration of refampicin/ketoconazole did not affect the exposure of diethylcarbamazine.
no
no (co-administration study)
Comment: Coadministration of refampicin/ketoconazole did not affect the exposure of diethylcarbamazine.
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
A brief introduction to the research achievement on the strategy and technical measures for interrupting the transmission of lymphatic filariasis in China.
2001
Compliance with the mass chemotherapy program for lymphatic filariasis.
2001 Dec
Lymphatic filariasis in kenya since 1910, and the prospects for its elimination: a review.
2001 Nov
Anthelmintics: a review.
2001 Oct-Dec
Mass DEC campaign for filariasis in a hyper endemic district of West Bengal.
2001 Sep
[Toxocariasis in Poznan region, Poland, in years 1990-2000].
2002
[Technical measures of filariasis elimination in Tengzhou City].
2002
Carbamazepine-provoked hepatotoxicity and possible aetiopathological role of glutathione in the events. Retrospective review of old data and call for new investigation.
2002
Subconjunctival Loa Loa worm: case report.
2002
The impact of single-dose diethylcarbamazine treatment of bancroftian filariasis in a low-endemicity setting in Egypt.
2002 Aug
Modelling the epidemiology, transmission and control of lymphatic filariasis.
2002 Dec
Use of floating layers of polystyrene beads to control populations of the filaria vector Culex quinquefasciatus.
2002 Dec
Cost-effectiveness of the use of vector control and mass drug administration, separately or in combination, against lymphatic filariasis.
2002 Dec
Operational issues in the control of the vectors of Brugia.
2002 Dec
Progress towards, and challenges for, the elimination of filariasis from Pacific-island communities.
2002 Dec
Detection of Onchocerca volvulus infection in low prevalence areas: a comparison of three diagnostic methods.
2002 Dec
Bancroftian filariasis: clinical parasitologic and serologic evaluation after 4 years applying two antifilarial regimens.
2002 Dec
Major progress toward eliminating lymphatic filariasis.
2002 Dec 5
Mass treatment to eliminate filariasis in Papua New Guinea.
2002 Dec 5
New goals set for filariasis elimination in India.
2002 Jul
Efficacy of co-administration of albendazole and diethylcarbamazine against geohelminthiases: a study from South India.
2002 Jun
Mass drug administration to treat lymphatic filariasis.
2002 Jun 1
Young male with pancytopenia: an unusual cause.
2002 May
Case 1-2002: Loa loa.
2002 May 30
Electron microscopic and molecular identification of Wolbachia endosymbionts from Onchocerca lupi: implications for therapy.
2002 May 30
[Asthenoscopic problems with a subconjunctival worm].
2002 Nov
Neoplastic change in Onchocerca volvulus and its relation to ivermectin treatment.
2002 Nov
Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells.
2002 Nov
Prevalence of diurnally subperiodic bancroftian filariasis among the Nicobarese in Andaman and Nicobar Islands, India: effect of age and gender.
2002 Nov
Targeting of children in filariasis mass drug administration.
2002 Nov 2
Case report: intraocular localization of Mansonella perstans in a patient from south Chad.
2002 Nov-Dec
Red blood cell antioxidant levels in Wuchereria bancrofti infection.
2002 Oct
Microfilaria in a thyroid nodule which resolved on treatment.
2002 Oct
Treatment of Brugia timori and Wuchereria bancrofti infections in Indonesia using DEC or a combination of DEC and albendazole: adverse reactions and short-term effects on microfilariae.
2002 Oct
The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole.
2002 Sep
The influence of the mass administration of diethylcarbamazine, alone or with albendazole, on the prevalence of filarial antigenaemia.
2002 Sep
The effect of six rounds of single dose mass treatment with diethylcarbamazine or ivermectin on Wuchereria bancrofti infection and its implications for lymphatic filariasis elimination.
2002 Sep
Efficacy and sustainability of a footcare programme in preventing acute attacks of adenolymphangitis in Brugian filariasis.
2002 Sep
Statistical issues in the assessment of the evidence for an interaction between factors in epilepsy trials.
2002 Sep 30
Targeting apoptotic signalling pathway and pro-inflammatory cytokine expression as therapeutic intervention in TPE induced lung damage.
2003
A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp.
2003
Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India.
2003 Apr
Long-term population migration: an important aspect to be considered during mass drug administration for elimination of lymphatic filariasis.
2003 Apr
Long-term follow-up of treatment with diethylcarbamazine on anti-filarial IgG4: dosage, compliance, and differential patterns in adults and children.
2003 Jan
Serum immunoglobulin G4 antibodies to the recombinant antigen, Ll-SXP-1, are highly specific for Loa loa infection.
2003 Jan 1
Relationships between Wuchereria bancrofti microfilaria counts in human blood and parasite uptake and maturation in Culex pipiens, with observations on the effects of diethylcarbamazine treatment on these parameters.
2003 Mar
Setaria cervi: in vitro released collagenases and their inhibition by Wuchereria bancrofti infected sera.
2003 Mar
Strategic options for global lymphatic filariasis elimination.
2003 May
Ensuring supplies of quality diethylcarbamazine citrate (DEC).
2003 May
Lymphatic filariasis.
2003 May 16

Sample Use Guides

Lymphatic filariasis: 6 mg/kg daily for 12 days administered orally, preferably in divided doses after meals (W. bancrofti infection); 3-6 mg/kg daily for 6-12 days administered orally, preferably in divided doses after meals (B. malayi and B. timori infections). Tropical pulmonary eosinophilia: a dose of 8 mg/kg daily for 14 days repeated, as necessary, if symptoms return.
Route of Administration: Oral
Larvae of nocturnally subperiodic Brugia malayi was inhibited under incubation with diethylcarbamazine at concentration of 10(-5) M.
Name Type Language
DIETHYLCARBAMAZINE
INN   MI   WHO-DD  
INN  
Official Name English
N,N-DIETHYL-4-METHYL-1-PIPERAZINECARBOXAMIDE
Systematic Name English
DIETHYLCARBAMAZINE [WHO-DD]
Common Name English
DIETHYLCARBAMAZINE [INN]
Common Name English
CAMIN
Brand Name English
DIETHYLCARBAMAZINE [MI]
Common Name English
Classification Tree Code System Code
WHO-VATC QP52AH02
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
NDF-RT N0000175481
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
NCI_THESAURUS C250
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
WHO-ATC P02CB02
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
CFR 21 CFR 520.623
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
CFR 21 CFR 520.620
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.1.2
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
Code System Code Type Description
PUBCHEM
3052
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
PRIMARY
DRUG CENTRAL
873
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
PRIMARY
ECHA (EC/EINECS)
202-023-3
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
PRIMARY
MERCK INDEX
M4398
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
PRIMARY Merck Index
CAS
90-89-1
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
PRIMARY
NCI_THESAURUS
C65378
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
PRIMARY
MESH
D004049
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
PRIMARY
WIKIPEDIA
DIETHYLCARBAMAZINE
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
PRIMARY
INN
1540
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
PRIMARY
EPA CompTox
90-89-1
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
PRIMARY
EVMPD
SUB07111MIG
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
PRIMARY
DRUG BANK
DB00711
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
PRIMARY
FDA UNII
V867Q8X3ZD
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
PRIMARY
RXCUI
3384
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
PRIMARY RxNorm
ChEMBL
CHEMBL684
Created by admin on Sat Jun 26 04:23:20 UTC 2021 , Edited by admin on Sat Jun 26 04:23:20 UTC 2021
PRIMARY